Key Points
- EVP Craig Hopkinson sold 4,000 shares on Jan. 2 at an average of $28.00 for a $112,000 transaction, reducing his stake by 6.08% to 61,740 shares (≈$1.73M), as disclosed on an SEC Form 4.
- Alkermes shares traded around $28.26 (near its 50-/200-day averages), the company reported an EPS beat ($0.49 vs. $0.41) and revenue beat last quarter, and set FY2025 guidance of $1.360–$1.470 EPS.
- Analyst sentiment is a “Moderate Buy” with an average price target of $44.69 (1 Strong Buy, 11 Buy, 4 Hold), and about 95.21% of shares are held by hedge funds and institutional investors.
Alkermes plc (NASDAQ:ALKS - Get Free Report) EVP Craig Hopkinson sold 4,000 shares of the firm's stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $28.00, for a total transaction of $112,000.00. Following the completion of the sale, the executive vice president directly owned 61,740 shares in the company, valued at approximately $1,728,720. This trade represents a 6.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Alkermes Trading Up 1.0%
Shares of NASDAQ:ALKS opened at $28.26 on Friday. The company has a 50-day moving average price of $29.42 and a 200-day moving average price of $29.06. The company has a market cap of $4.67 billion, a price-to-earnings ratio of 13.99 and a beta of 0.48. Alkermes plc has a 12 month low of $25.17 and a 12 month high of $36.45.
Alkermes (NASDAQ:ALKS - Get Free Report) last posted its earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.08. The company had revenue of $394.19 million for the quarter, compared to analysts' expectations of $355.23 million. Alkermes had a return on equity of 21.81% and a net margin of 22.27%.Alkermes's quarterly revenue was up 4.3% on a year-over-year basis. During the same period last year, the firm earned $0.73 earnings per share. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. As a group, research analysts forecast that Alkermes plc will post 1.31 EPS for the current fiscal year.
Hedge Funds Weigh In On Alkermes
Several large investors have recently made changes to their positions in the business. Diversified Trust Co raised its stake in Alkermes by 0.8% during the second quarter. Diversified Trust Co now owns 44,232 shares of the company's stock valued at $1,265,000 after buying an additional 372 shares during the last quarter. Orion Porfolio Solutions LLC increased its holdings in shares of Alkermes by 4.5% during the third quarter. Orion Porfolio Solutions LLC now owns 8,762 shares of the company's stock valued at $263,000 after acquiring an additional 376 shares in the last quarter. Horizon Investments LLC raised its position in shares of Alkermes by 0.9% in the 3rd quarter. Horizon Investments LLC now owns 43,002 shares of the company's stock worth $1,290,000 after purchasing an additional 387 shares during the last quarter. AMG National Trust Bank boosted its stake in Alkermes by 0.6% in the 3rd quarter. AMG National Trust Bank now owns 60,175 shares of the company's stock worth $1,805,000 after purchasing an additional 388 shares in the last quarter. Finally, Tidal Investments LLC grew its position in Alkermes by 1.1% during the 2nd quarter. Tidal Investments LLC now owns 35,130 shares of the company's stock valued at $1,005,000 after purchasing an additional 395 shares during the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of analysts recently commented on the company. Wells Fargo & Company dropped their price target on Alkermes from $42.00 to $37.00 and set an "overweight" rating for the company in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Alkermes in a research report on Monday. Mizuho lifted their target price on shares of Alkermes from $40.00 to $45.00 and gave the company an "outperform" rating in a research note on Monday, October 27th. Wall Street Zen downgraded shares of Alkermes from a "strong-buy" rating to a "buy" rating in a research note on Sunday, November 9th. Finally, Truist Financial raised their price objective on shares of Alkermes from $50.00 to $55.00 and gave the stock a "buy" rating in a report on Monday, November 17th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $44.69.
Check Out Our Latest Report on ALKS
Alkermes Company Profile
(
Get Free Report)
Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.
Alkermes' commercial franchise features several approved products.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
